Key Roles of Inflammation in Atherosclerosis : Mediators Involved in Orchestrating the Inflammatory Response and Its Resolution in the Disease Along with Therapeutic Avenues Targeting Inflammation
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature..
Inflammation is a critical driver of all stages of atherosclerosis, from lesion development to plaque rupture. Cytokines are mediators of the immune response and in atherosclerosis, the balance of anti- and pro-inflammatory cytokines is tipped in favor of the latter, resulting in persistent and unresolved inflammation. Although reducing plasma cholesterol levels mainly via the use of statins has positively impacted patient outcomes and reduced mortality rates, the presence of significant residual inflammation and cardiovascular risk posttherapy emphasizes the prevailing risk of primary and secondary events driven by inflammation independently of hyperlipidemia. Given the dominant role of inflammation in driving pathogenesis, alternative therapeutic avenues beyond targeting lowering of plasma lipids are required. This chapter will discuss the role of inflammation and pro-inflammatory cytokines in driving atherogenesis and disease progression, the therapeutic potential of targeting cytokines for atherosclerosis and promising avenues in this area.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2419 |
|---|---|
| Enthalten in: |
Methods in molecular biology (Clifton, N.J.) - 2419(2022) vom: 02., Seite 21-37 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chan, Yee-Hung [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atherosclerosis |
|---|
| Anmerkungen: |
Date Completed 04.03.2022 Date Revised 06.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-1-0716-1924-7_2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337691975 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337691975 | ||
| 003 | DE-627 | ||
| 005 | 20231225235006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-1-0716-1924-7_2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337691975 | ||
| 035 | |a (NLM)35237956 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chan, Yee-Hung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Key Roles of Inflammation in Atherosclerosis |b Mediators Involved in Orchestrating the Inflammatory Response and Its Resolution in the Disease Along with Therapeutic Avenues Targeting Inflammation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2022 | ||
| 500 | |a Date Revised 06.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Inflammation is a critical driver of all stages of atherosclerosis, from lesion development to plaque rupture. Cytokines are mediators of the immune response and in atherosclerosis, the balance of anti- and pro-inflammatory cytokines is tipped in favor of the latter, resulting in persistent and unresolved inflammation. Although reducing plasma cholesterol levels mainly via the use of statins has positively impacted patient outcomes and reduced mortality rates, the presence of significant residual inflammation and cardiovascular risk posttherapy emphasizes the prevailing risk of primary and secondary events driven by inflammation independently of hyperlipidemia. Given the dominant role of inflammation in driving pathogenesis, alternative therapeutic avenues beyond targeting lowering of plasma lipids are required. This chapter will discuss the role of inflammation and pro-inflammatory cytokines in driving atherogenesis and disease progression, the therapeutic potential of targeting cytokines for atherosclerosis and promising avenues in this area | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a IL-1β | |
| 650 | 4 | |a Inflammasome | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Macrophages | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Inflammation Mediators |2 NLM | |
| 700 | 1 | |a Ramji, Dipak P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Methods in molecular biology (Clifton, N.J.) |d 1984 |g 2419(2022) vom: 02., Seite 21-37 |w (DE-627)NLM074849794 |x 1940-6029 |7 nnns |
| 773 | 1 | 8 | |g volume:2419 |g year:2022 |g day:02 |g pages:21-37 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-1-0716-1924-7_2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2419 |j 2022 |b 02 |h 21-37 | ||